Systemic fungal infections in renal diseases

Area of Science:

• Nephrology
• Mycology
• Infectious Diseases

Background:

• Invasive fungal infections (IFIs) present a significant clinical challenge, particularly in immunocompromised patients and those with renal dysfunction.
• High morbidity and mortality rates are associated with IFIs in these populations.
• Current management strategies for IFIs in renal dysfunction have limited safety profiles and high costs.

Purpose of the Study:

• To review the challenges in managing invasive mycosis in patients with renal dysfunction, including acute renal failure, chronic kidney disease, and renal transplant recipients.
• To evaluate treatment options for invasive fungal infections in patients with impaired kidney function.
• To highlight the potential benefits of liposomal formulations of Amphotericin B.

Main Methods:

• This review synthesizes current literature on the management of invasive fungal infections in patients with renal dysfunction.
• It discusses the clinical issues, treatment guidelines, and therapeutic alternatives.
• Focus is placed on comparing conventional Amphotericin B with its liposomal preparations.

Main Results:

• Intravenous liposomal Amphotericin B demonstrates an improved tolerability profile compared to conventional Amphotericin B.
• Liposomal Amphotericin B is presented as an effective alternative for treating IFIs in patients with renal dysfunction.
• Two commercial liposomal preparations, Fungisome and Ambisome, are available.

Conclusions:

• Liposomal Amphotericin B offers a safer and more tolerable treatment option for invasive fungal infections in patients with renal dysfunction.
• The choice of liposomal formulation should consider disease severity, degree of renal dysfunction, and cost.
• Further research may be warranted to optimize the use of liposomal Amphotericin B in this patient group.